Abstract 2531: FCN-683, a novel second-generation BCL-2 inhibitor, is highly potent, selective and efficacious against clinically relevant venetoclax-resistant mutations

Authors: Shu (Sophie) Lin, Hongbin Liu, Rui Tan, Weipeng Zhang, Chengxi He, Yue Rong, Zhuo Huang, Jinhua Yu, Yunling Wang, Yangli Qi, Xingdong Zhao, Lihua Jiang, Yanxin Liu, Xilei Wang, Zongyao Zou, Jing Sun, Yuwei Gao, Weibo Wang, Xiaohui Guan, Yifang Wu

Published: 2023-04-04

DOI: 10.1158/1538-7445.am2023-2531

Source: Full article